Scots Hammer PTC's Translarna As EU Reviews Conditional Approval
This article was originally published in Scrip
In another blow for PTC Therapeutics' orphan drug for Duchenne muscular dystrophy, Translarna (ataluren), the Scottish Medicines Consortium has rejected the use of the product on the national health service, saying that the company had failed to justify its high cost in relation to its clinical benefits. The move comes in wake of the US Food and Drug Administration's February refusal to accept PTC's filing for Translarna.
You may also be interested in...
While the German pricing and reimbursement authority continues to argue that there is insufficient comparative data for drugs that are granted conditional marketing authorization, health technology assessment bodies and payers in the EU generally agree that they need to find innovative solutions to work around these evidence gaps.
The biotech submitted an NDA to FDA for its DMD drug in hopes of succeeding where other companies have failed.
A resolution adopted by the EU’s legislative body includes ways of making Europe more resilient to future pandemics and supply chain risks, and ensuring equitable access to affordable vaccines and medicines. Proposals from the European Parliament to share IP and knowledge have been welcomed by medicines access campaigners.